Figure 2
From: A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma
Impact of KRAS and BRAF mutations in CRC and the Kaplan–Meier. Survival analysis. (A) Colorectal cancer patients with KRAS mutations had reduced overall survival of 63.5% at 5 years compared with 73.5% without KRAS mutations (p = 0.0078). (B) In CRC patients, there was no significance in survival between BRAF mutated and non mutated cases. (p = 0.3310).